What is the latest published ALNY stock rating?

Alnylam Pharmaceuticals, Inc. is shown with Strong Buy in the latest published report, analyzed 2026-05-13. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ALNY analysis?

The full latest published report, analyzed 2026-05-13, lives at /stocks/ALNY/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for ALNY?

The latest published report analyzed 2026-05-13 gives ALNY a fair value of USD 666 and a potential value of USD 975. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the ALNY page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-13). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

ALNY Stock: Fundamentals & Analysis | StockMarketAgent.AI

ورود Start free

Alnylam Pharmaceuticals, Inc. (ALNY)

NASDAQ: ALNY · USD

$233

+5.76 (+2.5%)· Recorded snapshot

StockMarketAgent Research · Analyzed 2026-05-13

Our latest published analysis: ALNY rated Strong Buy

Alnylam Pharmaceuticals, Inc.'s published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$666 / share

Potential value

$975 / share

Upside to FV

+128.0%

from $233

Moat

9/10

Wide

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$39.0B

Revenue (ttm)	4.8B

Net income (ttm)	774.7M

EPS (ttm)	$5.62

Shares out	133.8M

P/E (trailing)	41.4x

P/E (forward)	21.1x

Volume	1,406,686

Beta	0.27

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 4.8B
Net income (ttm): 774.7M
EPS (ttm): $5.62
P/E (trailing): 41.4x
P/E (forward): 21.1x
Market cap: $39.0B

Item	P1	P2	P3	P4	Trend
Period	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$1.04B	$1.83B	$2.25B	$3.71B	+53.0%
Gross profit	$868.6M	$1.52B	$1.92B	$3.03B	+51.7%
Operating income	$-971.0M	$-312.3M	$-235.5M	$575.8M	—
Net income	$-1.13B	$-440.2M	$-278.2M	$313.7M	—
EPS (diluted)	$-9.30	$-3.52	$-2.18	$2.33	—
EBITDA	$-926.6M	$-258.2M	$-178.8M	$631.4M	—
R&D	$883.0M	$1.00B	$1.13B	$1.32B	+14.3%
SG&A	$770.7M	$795.6M	$975.5M	$1.21B	+16.3%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ARGX	argenx SE	56.1B	31.5x	9.4x	57.0%	+63.3%	+7.5%	خرید قوی
AXON	Axon Enterprise Inc.	34.4B	176.1x	10.6x	1.2%	+31.9%	-43.4%	فروش
COIN	Coinbase Global, Inc.	42.8B	—	7.0x	4.1%	+4.2%	-55.8%	فروش
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	فروش
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	کاهش موقعیت
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	کاهش موقعیت

Sensitivity: Ke × terminal growth

Ke ↓ / g →	2.5%	3.0%	3.5%	4.0%	4.5%
5.0%	$936	$1,165	$1,165	$1,165	$1,165
6.0%	$666	$778	$936	$1,165	$1,165
7.0%	$516	$582	$666	$778	$936
8.0%	$422	$464	$516	$582	$666
9.0%	$366	$386	$422	$464	$516

Scorecard

Published factor rows and weighted composite

Valuation9.5

Management7.3

Balance Sheet5.0

Profitability7.5

Revenue Growth9.0

Risk Assessment5.5

Competitive Moat9.0

Earnings Quality7.5

Capital Efficiency7.5

Weighted composite

7.5/10

High quality

Category	Score	Reading
Valuation	9.5
Management	7.3
Balance Sheet	5.0
Profitability	7.5
Revenue Growth	9.0
Risk Assessment	5.5
Competitive Moat	9.0
Earnings Quality	7.5
Capital Efficiency	7.5

All ALNY indicators

Market & fundamental data

Available fields

248

Groups with data

Currency

USD

Showing 248 of 248 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001178670
Company name	Alnylam Pharmaceuticals, Inc.
Country	United States
Country code	US
CUSIP number	02043Q107
Earnings date	2026-10-29
Earnings time	bmo
Employees	2,500
Employees change	270
Employees growth	12.11%
Enterprise value	$30.8B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2002
In index	NASDAQ100
Industry	Biotechnology
IPO date	2004-05-28
Is primary listing	Yes
Is SPAC	No
ISIN number	US02043Q1076
Last 10-K release date	2026-02-12
Last earnings date	2026-07-30
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$31.1B
Market cap category	Large-Cap
Next earnings date	2026-10-29
Options	Yes
Price	$232.54
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ALNY
U.S. state	Massachusetts
Website	https://www.alnylam.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	29.14x
Earnings yield	2.42%
EV/Earnings	39.35x
EV/EBIT	30.49x
EV/EBITDA	28.91x
EV/FCF	37.18x
EV/Sales	6.35x
FCF / EV yield	2.69%
FCF yield	2.66%
Forward EV/Sales	4.81x
Forward P/E	28.54x
Forward P/S	4.86x
Graham number	35.78008
Graham upside	-84.46%
P/(FCF - SBC) ratio	63.75x
P/(OCF - SBC) ratio	53.56x
P/B ratio	22.4x
P/E ratio	41.38x
P/FCF ratio	37.57x
P/OCF ratio	33.78x
P/S ratio	6.41x
Price / tangible book value	22.75x
Price/EBITDA ratio	29.21x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	20.81%
EBITDA margin	21.95%
FCF margin	17.07%
Gross margin	79.65%
Operating margin	20.81%
Pretax margin	15.95%
Profit margin	16.13%
Profit per employee	$309,884
Profitable quarters	4
Profitable years	1
Revenue per employee	$1.9M
ROA	12.34%
ROA (5Y)	-5.39%
ROCE	24.71%
ROE	96.55%
ROIC	96.6%
SBC / revenue	7.01%
Tax / revenue	-0.18%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth (QoQ)	-19.78%
EPS growth quarters	4
EPS growth years	3
FCF growth (Q)	152.82%
FCF growth (QoQ)	500.04%
Gross profit growth	85.83%
Gross profit growth (Q)	57.36%
Gross profit growth 3Y	56.17%
Gross profit growth 5Y	46.2%
Net income growth (QoQ)	-20.15%
Net income growth quarters	4
Net income growth years	3
OCF growth (Q)	151.7%
OCF growth (QoQ)	363.41%
Revenue growth	95.14%
Revenue growth (Q)	66.86%
Revenue growth (QoQ)	10.6%
Revenue growth 10Y	66.17%
Revenue growth 3Y	57.17%
Revenue growth 5Y	47.52%
Revenue growth quarters	7
Revenue growth years	7

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-91.9M
Depreciation and amortization	$54.8M
EBIT	$999.8M
EBITDA	$1.1B
EPS	$5.62
FCF per share	$6.13
Financing cash flow	$-377M
Free cash flow	$819.9M
Free cash flow minus SBC	$483.2M
Gross profit	$3.8B
Income taxes	$-8.4M
Investing cash flow	$74.9M
Net borrowing	$-546.9M
Net cash flow	$593.6M
Net income	$774.7M
Operating cash flow minus SBC	$575.2M
Operating income	$999.8M
Revenue	$4.8B
Stock-based compensation	$336.6M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	7.58
Book value per share	$10.13
Debt / EBITDA	2.64
Debt / equity	2.21
Debt / FCF	3.64
Interest coverage	3.52
Long-term assets	$938.6M
Long-term liabilities	$2.7B
Net cash (debt)	$320.7M
Net cash / market cap	1.04%
Net cash growth	172.09%
Net debt / EBITDA	-0.3
Net debt / equity	-0.24
Net debt / FCF	-0.39
Piotroski F-Score	6
Property, plant and equipment	$737.5M
Shareholders' equity	$1.4B
Tangible book value	$1.4B
Tangible book value per share	$10.13
Total assets	$5.6B
Total cash	$3.3B
Total debt	$3B
Total liabilities	$4.2B
WACC	5.89%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.95
Current assets	$4.6B
Current liabilities	$1.5B
Current ratio	3.05
Inventory turnover	11.58
Net working capital	$104M
Quick ratio	2.79
Working capital	$3.1B
Working capital turnover	1.76

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-7.12%
Dividend yield	0%
Shareholder yield	-7.12%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	533.11%
10Y return CAGR	20.27%
10Y total return	533.11%
150-day SMA	$272.14
15Y price change	2,593.89%
15Y return CAGR	24.55%
15Y total return	2,593.89%
1D price change	2.54%
1M price change	-10.44%
1M total return	-10.44%
1W price change	-0.63%
1W total return	-0.63%
1Y price change	-52.1%
1Y return CAGR	-52.12%
1Y total return	-52.1%
20-day SMA	$227.08
200-day SMA	$287.45
20Y price change	1,263.77%
20Y return CAGR	13.96%
20Y total return	1,263.77%
3M price change	-17.65%
3M total return	-17.65%
3Y price change	51.06%
3Y return CAGR	14.74%
3Y total return	51.06%
50-day SMA	$239.09
50-day SMA vs 200-day SMA	50under200
52-week high	$484.61
52-week high date	2025-10-28
52-week low	$197.81
52-week low date	2026-07-30
5Y price change	19.93%
5Y return CAGR	3.7%
5Y total return	19.93%
6M price change	-25.69%
6M total return	-25.69%
All-time high	$495.55
All-time high date	2025-10-20
All-time low	$3.65
All-time low date	2004-08-18
Average true range (ATR)	$8.58
Average volume	1.4M
Beta (1Y)	0.57
Beta (2Y)	0.93
Beta (5Y)	0.27
Change from 52-week high	-52.02%
Change from 52-week low	17.56%
Change from all-time high	-53.74%
Change from all-time low	6,180.82%
Change from open	4.41%
Day's gap	-1.79%
Dollar volume	$327.1M
High price	$232.61
Low price	$222.13
Monthly RSI	40.61
Open price	$222.72
Position in 52-week range	99.33%
Premarket change	-1.18%
Premarket close	$226.79
Premarket price	$224.11
Premarket volume	1.3K
Previous close	$226.79
Price vs 150-day SMA	-15.76%
Price vs 20-day SMA	0.95%
Price vs 200-day SMA	-20.25%
Price vs 50-day SMA	-4.12%
Relative volume	1.03
RSI	47.06
Sharpe ratio	-1.36
Sharpe ratio (3Y)	0.39
Sharpe ratio (5Y)	0.21
Sortino ratio	-1.51
Sortino ratio (3Y)	0.73
Sortino ratio (5Y)	0.45
Volume	1.4M
Weekly RSI	40.06
YTD price change	-42.35%
YTD total return	-42.35%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	133.2M
Float percentage	99.56%
Shares change (QoQ)	0.04%
Shares change (YoY)	7.12%
Shares held by insiders	0.39%
Shares held by institutions	100.86%
Shares outstanding	133.8M
Short % of float	5.79%
Short % of shares	5.76%
Short ratio	5.2 days

سابقهٔ رتبه‌بندی

رتبه‌ای که نسخهٔ پژوهشی منتشرشدهٔ هر ماه داشت. رتبه قیمت در تاریخ تحلیل را با ارزش منصفانه مقایسه می‌کند و سابقه‌ای از درستی یا نادرستی ارزیابی نیست.

سال	دی	بهمن	اسفند	فروردین	اردیبهشت	خرداد	تیر	مرداد	شهریور	مهر	آبان	آذر
2026

خرید قوی

Alnylam Pharmaceuticals, Inc. (ALNY)

Our latest published analysis: ALNY rated Strong Buy

Price

Financial snapshot

Fair-value bridge

Latest news · ALNY

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All ALNY indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ALNY

Frequently asked questions

سابقهٔ رتبه‌بندی